Title:
COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING IMMUNE CHECKPOINT INHIBITOR-RESISTANT CANCER
Document Type and Number:
WIPO Patent Application WO/2021/006714
Kind Code:
A1
Abstract:
The present invention relates to a composition for preventing, ameliorating or treating immune checkpoint inhibitor-resistant cancer, comprising, as an active ingredient, a binding molecule capable of specifically binding to leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is a protein present on the surface of regulatory T cells (Treg). The binding molecule specific to the Lrig-1 protein according to the present invention suppresses the function of regulatory T cells in which the Lrig-1 protein is expressed at high levels, such as regulatory T cells in tumor infiltrating lymphocytes (TIL) or activated regulatory T cells, thereby very effectively preventing a phenomenon in which the function of effective T cells is suppressed by the regulatory T cells. Accordingly, the binding molecule specific to the Lrig-1 protein can effectively prevent, ameliorate or treat immune-evasive cancer, that is, cancer with resistance to immune checkpoint inhibitors.
More Like This:
| WO/2021/050925 | METHODS FOR MAKING AUDITORY PROGENITOR CELLS AND USES THEREOF |
| WO/2022/251311 | METHODS OF QUANTIFYING ANTI-CD40 ANTIBODIES |
| WO/2021/089609 | MULTISPECIFIC ANTIBODY |
Inventors:
KIM BEOM SEOK (KR)
KIM JUNG HO (KR)
KIM JUNG HO (KR)
Application Number:
PCT/KR2020/009181
Publication Date:
January 14, 2021
Filing Date:
July 13, 2020
Export Citation:
Assignee:
GOOD T CELLS INC (KR)
International Classes:
C07K16/28; A61K39/00; A61K47/68; A61P35/00
Domestic Patent References:
| WO2015187359A1 | 2015-12-10 |
Foreign References:
| KR20180117067A | 2018-10-26 | |||
| US20150239964A1 | 2015-08-27 | |||
| KR20140013873A | 2014-02-05 | |||
| KR20180105232A | 2018-09-27 | |||
| KR20190084098A | 2019-07-15 |
Other References:
JULIAN A. MARIN-ACEVEDO, BHAGIRATHBHAI DHOLARIA, AIXA E. SOYANO, KEITH L. KNUTSON, SARANYA CHUMSRI, YANYAN LOU: "Next generation of immune checkpoint therapy in cancer: new developments and challenges", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 11, no. 1, 1 December 2018 (2018-12-01), XP055642850, DOI: 10.1186/s13045-018-0582-8
See also references of EP 3998284A4
See also references of EP 3998284A4
Attorney, Agent or Firm:
LEE, Jae Young (KR)
Download PDF: